Teneobio’s Lead Candidate, TNB-383B, Receives Orphan Drug Designation from the FDA for the Treatment of Multiple Myeloma
November 06, 2019 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that...
Teneobio Licenses Oncology Multispecific Product to Janssen
September 30, 2019 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that...
Teneobio Doses First Patient in Phase 1 Study of TNB-383B for the Treatment of Patients with Multiple Myeloma
July 15, 2019 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc. a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that...
Teneobio Announces US FDA Approval of the Investigational New Drug Application for TNB-383B and the Initiation of Phase I Clinical Studies in Multiple Myeloma Patients
April 29, 2019 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that their investigational new drug application (IND) for TNB-383B, a bispecific...
Teneobio Announces Research Collaboration with Janssen to Develop Multispecific Antibodies for Oncology
July 09, 2018 08:00 ET
|
TeneoBio, Inc
MENLO PARK, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Teneobio, Inc., a next generation multi-specific antibody therapeutics company, announced today the initiation of a research collaboration and...
Teneobio Announces a Strategic Alliance with TESARO to Develop the Next Generation of Immuno-Oncology, Multispecific Antibodies
January 08, 2018 08:00 ET
|
TeneoBio, Inc
MENLO PARK, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Teneobio, Inc., a next generation multi-specific antibody therapeutics company announced today the initiation of a research collaboration and...
TeneoBio’s Next Gen Multivalent anti-BCMAxCD3, TNB-383B, and Anti-BCMA UniDabs for CAR T-Cell Therapy of Multiple Myeloma Highlighted at the American Society of Hematology
December 11, 2017 08:00 ET
|
TeneoBio, Inc
MENLO PARK, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- TeneoBio, Inc. yesterday presented preclinical data on its lead therapeutic candidate, TNB-383B, a multivalent anti-BCMAxCD3 at the American...
Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy
May 22, 2017 08:00 ET
|
TeneoBio, Inc
MENLO PARK, Calif. and SAN DIEGO, May 22, 2017 (GLOBE NEWSWIRE) -- Teneobio, Inc. and Poseida Therapeutics, Inc. today announced that they have entered a commercial license agreement for the use of...
Teneobio’s Next Generation T Cell Redirection Antibody Platform for Cancer Biotherapeutics Offers Prospects of Reducing Cytokine Release
May 01, 2017 08:00 ET
|
TeneoBio, Inc
MENLO PARK, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Teneobio, Inc, a next-generation antibody therapeutics company, announced today at the Protein Engineering Summit (PEGS) in Boston the discovery...
Open Monoclonal Technology Announces OmniAb™ License to Seattle Genetics
November 02, 2015 08:00 ET
|
TeneoBio, Inc
PALO ALTO, Calif., Nov. 02, 2015 (GLOBE NEWSWIRE) -- Open Monoclonal Technology, Inc. (OMT) today announced a license that provides Seattle Genetics, Inc. with access to OMT’s proprietary...